NEW YORK, Oct. 31, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
US Intranasal Drug Delivery Industry
http://www.reportlinker.com/p0397796/US-Intranasal-Drug-Delivery-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology
This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 75 companies including many key and niche players such as Aegis Therapeutics LLC, Alza Corporation, AptarGroup, Inc., Archimedes Pharma Limited, AstraZeneca Plc, MedImmune, Inc., Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Ikano Therapeutics Inc., Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., Marina Biotech, Inc., Merck & Co., Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc, Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
INTRANASAL DRUG DELIVERY MCP-1795
A US MARKET REPORT
CONTENTS
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 2
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
Drug Delivery: A Quick Primer 4
The Nose: An Attractive Avenue to Cross the Blood Brain Barrier 4
Self-Administration of Drugs Brings Intranasal Drug Delivery
Into the Spotlight 5
Research & Technology Opens Up New Therapeutic Areas for
Nasal Drug Delivery 5
Product Developments in the US Intranasal Drug Delivery
Market: 2007 6
R&D: Critical to the Commercialization of Intranasal Drug
Delivery 6
Tight Junction Biology: A Key Speed Breaker in
Commercialization 6
RNA Interference (RNAi): A Tool to Manipulate Tight Junctions 7
Why Is Nasal Drug Delivery the Theme of All Drug Delivery
Research Projects? 7
Nasal Drug Delivery Devices & Equipment 7
Preservative Free Systems (P.F.S.) 7
Traditional Vs. Advanced Intranasal Drug Delivery Devices 9
Pitfalls Of Traditional Delivery Devices 9
The Promise of New Advanced Delivery Devices 9
Bi-Directional Nasal Drug Delivery: A Technology With a Huge
Potential 9
Benefits of Bi-Directional Delivery Authenticated Through
Research Studies 10
Market for Nasal Spray Devices in the US 11
GSK Looses Share to Merck, Following Patent Expiry of Flonase 11
Table 1: US Intra-Nasal Steroid Market for Allergic Rhinitis:
Sales of Leading Nasal Formulations for 2008 (includes
corresponding Graph/Chart) 11
Table 2: The US Nasal Drug Delivery Market for Allergic
Rhinitis: Sales Of Top Four Nasal Steroid Formulations for
The Year 2005 (In US$ Million) (includes corresponding
Graph/Chart) 12
3. MARKET DYNAMICS 13
Innovation in Drug Delivery: A Talisman For Success 13
Controlled Release Technology Is the Buzz Word 13
Target-Specific Delivery Devices: Of Critical Value 13
Safety and Cost: Primary Growth Drivers 13
Preservatives Losing Sheen in Nasal Spray Formulations 14
Multi-Dose Containers Evolve to Offer Resistance Against
Microbial Contamination 14
Bioavailability: An Important Facet of Intranasal Drug Delivery 14
Chemical Modification 15
Transient Modification & Limited Enzymatic Activity 15
Bioavailability of Large Molecules 15
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption 15
Mixed Opinions on Efficiency of Calcitonin Nasal Spray 15
Nasal Preparations Gaining Foothold in Cough and Allergic
Categories 16
Patent Expiries Impact Market Opportunities 16
4. TECHNOLOGY OVERVIEW 17
Intranasal Drug Delivery: A Descriptive Exposition 17
Nasal Physiology 17
Challenges Involved In Formulating Nasal Drugs 18
The Importance of Bioadhesion 19
Challenges Involved In Designing Devices 19
Overview of the Traditional Drug Administration Routes,
Molecular Weight Capabilities, and Dosage Range 20
Intranasal Drugs - Prescription (Rx) and Over-the- Counter (OTC) 20
Differences Between Systemic Delivery and Local Effects 20
Nasal Powders Vs Sprays 21
Nasal Drug Delivery Devices 21
Types of Drug Delivery Devices 22
Droppers 22
Sprays 22
Aerosol Containers/Inhalers 22
Pumps 22
Nasal Aspirator 22
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques 22
Table 3: US Market for Intranasal Drugs: Percentage share of
Topical and Systemic Drugs by value for the Years 2006 and
2015 23
Limitations of Intranasal Drug Delivery 23
Allergy 23
Definition 23
Symptoms 24
Allergic Rhinitis 24
Nasal Allergies 24
Table 4: US Market for Nasal Sprays: Top Five Nasal Sprays
for Cough, Cold, Sinus and Allergy Ranked by Dollar Retail
Sales for the Year Ended January 2008 (In US $ Million)
(includes corresponding Graph/Chart) 25
Table 5: US Market for Nasal Sprays, Drops and Inhalers: Top
10 Brands Ranked by Dollar Sales Through Drug Stores for the
Year Ended January 2008 (In US $ Million) (includes
corresponding Graph/Chart) 25
Table 6: US Market for Nasal Sprays, Drops and Inhalers: Top
10 Brands Ranked by Unit Sales Through Drug Stores for the
Year Ended January 2008 (In Thousand Units) (includes
corresponding Graph/Chart) 26
5. NASAL DRUGS: AN OVERVIEW 27
Nasal Drugs for Allergies 27
Corticosteroid Nasal Sprays 27
Flonase 27
Patanase 27
Beconase 28
Other Nasal Corticosteroid Drugs 28
Antihistamine Nasal Sprays 28
Astelin Nasal Spray 28
Otrivin Nasal Spray 28
Livostin Nasal Spray 28
Other Nasal Antihistamine Drugs 29
Select Brands of Allergy Relievers 29
Nasal Drugs for Postmenopausal Osteoporosis 29
Calcitonin-Salmon Nasal Spray 29
Miacalcin Nasal Spray 29
Fortical® Nasal Spray 29
Intranasal Pain Management Drugs 30
Stadol Nasal Spray 30
Rylomine 31
Imitrex 31
Migranal 31
Zolmitriptan Nasal Spray 31
Intranasal Analgesics For Treating Migraine 31
Select Intranasal Pain Management Products in Development 32
Intranasal Vaccination 32
Process of Intranasal Immunization 33
Market Drivers 33
"LAIV" Nasal Spray Flu Vaccine 34
FluMist® Vaccine From MedImmune 34
Intranasal Drugs for Sexual Dysfunction 34
Table 7: US Market for Intranasal Sexual Dysfunction Drugs:
Revenues for the Years 2010 through 2012 in US$ Million
(includes corresponding Graph/Chart) 35
Nasal Spray for Treating Vitamin B12 Deficiency 35
Nasal Spray for Aiding Smoking Cessation 35
Intranasal Drugs in Pipeline: 2008 and 2009 36
Other Intranasal Drugs in Pipeline 37
6. SELECT RESEARCH & DEVELOPMENT INITIATIVES 38
Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36
Nasal Spray 38
Archimedes Pharma Commences Phase III Trials for NasalFent® 38
Archimedes Presents New Clinical Data on NasalFent® 38
LigoCyte Commences Clinical Trials for Intranasal Norovirus
Vaccine 38
Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI
-100/150 39
Javelin Pharmaceuticals Commences Phase III studies for PMI-150 39
Nastech Commences Phase 2 Trials for Insulin Nasal Spray 39
ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray
in Children 39
TGAR01H from Fabre Kramer 40
Aegis Therapeutics Completes First Human Clinical Study on
Intravail® 40
Nastech Pharmaceutical Presents Clinical Test Results on
Parathyroid Hormone 40
Zolmitriptan Promises Relief for Cluster Headaches 41
CAIV-T: More Effective than Injectable Influenza Vaccines 41
Intranasal Therapeutics Conducts Study on Midazolam 41
Nastech Announces Phase I Results of Insulin Nasal Spray 42
Archimedes Completes Phase II Trials of NASALFENT 42
Intranasal Corticosteroid Proven Effective for Treating
Allergic Rhinitis 42
Aegis Files DMF for Intravail 43
Nasal Sprays: A New-Generation Treatment for Gynecological
Problems 43
Aegis Therapeutics Conducts Feasibility Study on Drug Delivery
Technology 43
GelVac Powder Delivery System Completes Phase I Clinical Trial 44
OptiNose Develops Intranasal Delivery System for Osteoporosis 44
Nastech Initiates Dose Ranging Study of PYY(3-36) 45
Valois Develops New Nasal Dispensing System 45
Rigel Pharmaceuticals to Initiate R112 Phase II Clinical Trial 45
MedPointe Pharmaceuticals Demonstrates ACT1 Study Results on
ASTELIN® 46
Bentley Pharmaceuticals Demonstrates Clinical Trial Results of
its Intra Nasal Insulin Spray 46
7. RECENT TECHNOLOGICAL DEVELOPMENTS 47
New-Generation Technologies and Devices 47
ViaNase from Kurve Technology 47
A New Product from OptiNose 47
Nastech's "Tight Junction Biology" Research Program 48
ChiSys™ Nasal Delivery Technology from Archimedes 48
8. PRODUCT INNOVATIONS/INTRODUCTIONS 49
TheraBiogen to Introduce TheraMax Cold & Flu Nasal Spray 49
Sinus Dynamics™ Unveils NasaTouch™ Nasal Delivery Device 49
3M Drug Delivery Systems Introduces Nasal MDI 49
MeadWestvaco Introduces Preservative-Free Nasal Pumps 49
GlaxoSmithKline Introduces Avamys Nasal Spray 50
9. PRODUCT INNOVATIONS/INTRODUCTIONS IN THE RECENT PAST- A
PERSPECTIVE BUILDER 51
Aegis Therapeutics Develops ProTek™ 51
Heel Launches Luffeel® in the US 51
Archimedes to Introduce Intranasal Formulation of Human Growth
Hormone 51
Sinofresh Launches SinoFresh™ Nasal & Sinus Care 51
PARI Respiratory Launches Nasal Drug Delivery Program 52
OptiNose to Develop New Range of Intranasal Products 52
OptiNose and Cambridge Consultants to Develop Advanced Nasal
Delivery Device 52
Kurve Technology Develops ViaNase ID™ 52
Upsher-Smith Introduces Fortical® Nasal Spray 53
Schering-Plough Launches New Formulation of NASONEX® 53
AstraZeneca Unveils Rhinocort Aqua in the US 53
10. RECENT INDUSTRY ACTIVITY 54
Upsher-Smith Acquires ITI-111 from Ikano Therapeutics 54
Hospira Acquires Javelin Pharmaceuticals 54
Archimedes Pharma Receives Approval for PecFent Nasal Spray 54
Cypress Bioscience Obtains Patent Rights for Carbetocin Therapy 55
MDRNA, Inc. Announces Change of Name 55
Prosonix Inks Product Co-Development and Licensing with Trimel
Biopharma 55
Serenity Pharmaceuticals and Allergan Sign Agreement 56
Ethicon Acquires Acclarent 56
Ikano's Midazolam Obtains Orphan Drug Designation 56
FDA Issues Not-Approvable Letter for Nastech's Generic
Calcitonin-Salmon 56
Trimel BioPharma Acquires Direct Haler 57
Lupin Takes Over AllerNaze™ Rights from Collegium Pharmaceutical 57
Nanotherapeutics Purchases DelSite Assets 57
Schering-Plough Merges with Merck 58
Valois Pharma and Nycomed Launch Spray Pump for Fentanyl 58
Phylogica and Aegis Therapeutics Collaborate 58
Intranasal Therapeutics is Now Ikano Therapeutics 58
FDA Clears Use of New Clone in Calcitonin Production of Unigene 58
Zelos Therapeutics Collaborates with Aegis Therapeutics 59
ImmuneRegen BioSciences Partners with LRRI 59
Avamys™ Nasal Spray Receives Approval in Europe 59
PMI-150 Receives Canadian Patent 59
11. CORPORATE ACTIVITY IN THE RECENT PAST-A PERSPECTIVE BUILDER 60
Javelin Releases Phase III Data of Rylomine Intranasal Morphine 60
FDA Recommends Supplemental Study for Javelin's PMI-150 60
Palatin Re-Acquires Bremelanotide Rights from King Pharma 60
USFDA Approves FluMist® for Young Children 61
USFDA Approves Veramyst Nasal Spray for Individuals Aged Two
Years and Above 61
Kurve Technology Inks Agreement with Schering-Plough 61
MedImmune Clarifies FDA Observations 61
FluMist(R) Receives FDA Approval for Refrigerated Formulation 61
Nastech Regains Rights for PTH1-34 Nasal Spray 61
NASONEX(R) Receives Ease-of-Use Commendation from Arthritis
Foundation 62
Aegis Therapeutics Establishes Cedar Therapeutics Inc. 62
EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray 62
Kurve Technologies Introduces Blog on Nasal Drug Delivery 62
Accentia Extends Agreement with Mayo Foundation 62
Nastech Signs Development and License Agreement with Amylin 63
MedImmune's FluMist Plant Gets FDA Approval 63
ShinNippon Subsidiaries Sign Licensing Agreement with Tokai
Pharmaceuticals 63
MeadWestvaco Acquires Saint-Gobain Calmar 63
Merck Terminates PYY3-36 Partnership with Nastech 64
Inspire Signs Licensing Agreement with Boehringer Ingelheim 64
P&G Partners with Nastech to Develop PTH(1-34) 64
Unigene Laboratories Signs Distribution Agreement with Tzamal
Bio Pharma 65
GlaxoSmithKline Seeks Marketing Approval for Fluticasone
Furoate in the US and Europe 65
Kurve Technology Relocates Corporate Headquarters 65
Kurve Inks an Agreement with DARA BioSciences 65
Kurve Enters into a Development Agreement with Schering-Plough 66
Altana Submits NDS for Approval of Ciclesonide Nasal Spray in
Canada 66
Altana Pharma AG Receives FDA Approval for Pediatric Use of
Omnaris 66
Intranasal Therapeutics Inc. Receives Financial Funding 66
FDA Completes Pre-Approval Inspections at Nastech's Washington
Facility 66
Kos Signs Exclusive License Agreement with SkyePharma 67
Bentley Signs Agreement with Biocon 67
Intranasal Therapeutics Files Patent Application for Synthetic
THC 67
Ionix Pharmaceuticals in Collaboration with Reckitt Benckiser
for Drug Development 67
University of Kentucky Receives Patent for new Intranasal Device 68
Intranasal Technology Extends Collaboration with Aegis
Therapeutics 68
Accentia Biopharmaceuticals Signs License Agreement with
Collegium Pharmaceuticals 68
Aegis Therapeutics Extends License Agreement with Intranasal
Technologies 69
Bentley Pharmaceuticals Signs Agreement with Dong Sung
Pharmaceuticals 69
Unigene Gets FDA Approval for Fortical Calcitonin- Salmon
Nasal Spray 69
OptiNose Signs Collaborative Agreement with MedPharm 69
West Pharmaceutical Divests Drug Delivery Business to
Archimedes Pharma 70
Nastech Pharmaceutical Receives FDA Approval for Nascobal
Nasal Spray 70
Par and Nastech Sign Licensing Agreement 70
Aegis Therapeutics Signs Licensing Agreement with University
of Alabama 70
ITI Receives a Patent for Sedation Inducing Nasal Drug 71
Inyx Bags Order from Australian OTC Drug Company 71
12. FOCUS ON SELECT GLOBAL PLAYERS 72
Aegis Therapeutics LLC (USA) 72
Alza Corporation (USA) 72
AptarGroup, Inc. (USA) 72
Archimedes Pharma Limited. (UK) 73
AstraZeneca Plc. (UK) 73
MedImmune, Inc. (USA) 73
Bayer Consumer Care (USA) 74
Bespak Plc. (UK) 74
GlaxoSmithKline Plc (UK) 74
Ikano Therapeutics Inc. (USA) 75
Javelin Pharmaceuticals, Inc. (USA) 75
Kurve Technology, Inc. (USA) 76
Marina Biotech, Inc. (USA) 76
Merck & Co., Inc. (USA) 76
Novartis AG (Switzerland) 77
OptiNose AS (Norway) 77
Pfizer, Inc. (USA) 77
Rexam Plc (UK) 78
Sanofi-Aventis S.A. (France) 78
Unigene Laboratories, Inc. (USA) 78
13. MARKET ANALYTICS 79
Table 8: US Recent Past, Current & Future Analysis for
Intranasal Drug Delivery by Therapeutic Area - Allergic
Infections, Analgesics, Osteoporosis, and Vaccinations Markets
Independently Analyzed by Annual Sales Figures in US$ Million
for Years 2007 through 2015 (includes corresponding
Graph/Chart) 79
Table 9: US Historic Review for Intranasal Drug Delivery by
Therapeutic Area - Allergic Infections, Analgesics,
Osteoporosis, and Vaccinations Markets Independently Analyzed
by Annual Sales Figures in US$ Million for Years 2000 through
2006 (includes corresponding Graph/Chart) 80
Table 10: US 11-Year Perspective for Intranasal Drug Delivery
by Therapeutic Area -Percentage Breakdown of Values Sales for
Allergic Infections, Analgesics, Osteoporosis, and
Vaccinations for Years 2005, 2010 & 2015 (includes
corresponding Graph/Chart) 81
COMPETITIVE LANDSCAPE
Total Companies Profiled: 75 (including Divisions/Subsidiaries - 90)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 53
Canada 2
Japan 3
Europe 27
France 3
Germany 5
The United Kingdom 13
Rest of Europe 6
Asia-Pacific (Excluding Japan) 5
------------------------------------------
To order this report:
: US Intranasal Drug Delivery Industry
Check our Real Time Industry Data
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article